Review




Structured Review

Arraystar inc human circrna array analysis
Human Circrna Array Analysis, supplied by Arraystar inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human circrna array analysis/product/Arraystar inc
Average 90 stars, based on 1 article reviews
human circrna array analysis - by Bioz Stars, 2026-04
90/100 stars

Images



Similar Products

90
CapitalBio Corporation human circrna array v2 microarray analysis
Human Circrna Array V2 Microarray Analysis, supplied by CapitalBio Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human circrna array v2 microarray analysis/product/CapitalBio Corporation
Average 90 stars, based on 1 article reviews
human circrna array v2 microarray analysis - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

90
Arraystar inc human circrna array analysis
Human Circrna Array Analysis, supplied by Arraystar inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human circrna array analysis/product/Arraystar inc
Average 90 stars, based on 1 article reviews
human circrna array analysis - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

90
Arraystar inc human circrnas analysis
Plasma circRNA expression pattern in healthy individuals and colon polyp and colon cancer patients. (A) The endoscopic diagnosis of healthy individuals (left panel) and colon polyp (central panel) and colon cancer (right panel) patients. (B) The schematic diagram of Arraystar assay performance in plasma <t>circRNAs.</t> (C) The differential expression of plasma circRNAs in polyp patients ( N = 5) and healthy individuals ( N = 5). The expression variation of circRNAs was assessed by the scatter plot between polyp patients and healthy individuals (left panel). The green lines represented fold change lines. The circRNAs above the top green line and below the bottom green line indicated more than 1.5-fold change of circRNAs between the two compared samples. The differential expression of circRNAs was analyzed by volcano plots between polyp patients and healthy individuals (right panel). Red points represented the differentially expressed circRNAs with statistical significance (1.5-fold upregulation and downregulation, P < 0.05). (D) The differential expression of plasma circRNAs in colon cancer ( N = 5) and colon polyp patients ( N = 5). The expression variation of circRNAs was assessed by the scatter plot between colon cancer and colon polyp patients (left panel). The green lines represented fold change lines. The circRNAs above the top green line and below the bottom green line indicated more than 1.5-fold change of circRNAs between the two compared samples. The differential expression of circRNAs was analyzed by volcano plots between colon cancer and colon polyp patients (right panel). Red points represented the differentially expressed circRNAs with statistical significance (1.5-fold upregulation and downregulation, P < 0.05). (E) The differential expression of plasma circRNAs in colon cancer patients ( N = 5) and healthy individuals ( N = 5). The expression variation of circRNAs was assessed by the scatter plot between colon cancer patients and healthy individuals (left panel). The green lines represented fold change lines. The circRNAs above the top green line and below the bottom green line indicated more than 1.5-fold change of circRNAs between the two compared samples. The differential expression of circRNAs was analyzed by volcano plots between cancer patients and healthy individuals (right panel). Red points represented the differentially expressed circRNAs with statistical significance (1.5-fold upregulation and downregulation, P < 0.05). (F–H) The composition of types in detectable circRNAs. (F) The composition of circRNA types in polyp and colon cancer patients. (I) The Venn analysis between upregulated circRNAs from colon cancer patients compared with colon polyp patients and downregulated circRNAs from colon polyp patients compared with healthy individuals. (J) The Venn analysis between downregulated circRNAs from colon cancer patients compared with colon polyp patients and upregulated circRNAs from colon polyp patients compared with healthy individuals. (K) The potential circRNA candidates were validated by performing real-time PCR in plasma from healthy individuals ( N = 15) and colon polyp ( N = 15) and colon cancer ( N = 15) patients. (L) The schematic diagram of circHADHA dynamic alteration in healthy individuals and colon polyp and colon cancer patients. **** P < 0.0001; ns, no significant difference.
Human Circrnas Analysis, supplied by Arraystar inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human circrnas analysis/product/Arraystar inc
Average 90 stars, based on 1 article reviews
human circrnas analysis - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

90
Arraystar inc human circrna microarray analysis
A novel up-regulated <t>circRNA</t> circ-ANXA7 is an independent prognostic factor for LUAD. a circ-ANXA7 up-regulation was found between LUAD tissues (n = 40) and non-tumor tissues (n = 40) by <t>microarray</t> analysis. Red: up-regulation and green: down-regulation. b Box plots visualizing a higher expression level of circ-ANXA7 in LUAD tissues than non-tumor tissues using qRT-PCR. c qRT-PCR was utilized to examine the relative expression levels of circ-ANXA7 between normal epithelial cells and LUAD cells. d Overall survival analysis between LUAD patients with high circ-ANXA7 expression and those with its low expression. e Multivariate regression analysis of circ-ANXA7 expression after adjusting other prognostic factors. f Western blot was presented to examine the expression of ANXA7 protein between normal epithelial cells and LUAD cells. g Immunohistochemistry of ANXA7 between adjacent normal tissues and LUAD tissues. Magnification: ×40; ×200. **p < 0.01
Human Circrna Microarray Analysis, supplied by Arraystar inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human circrna microarray analysis/product/Arraystar inc
Average 90 stars, based on 1 article reviews
human circrna microarray analysis - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

Image Search Results


Plasma circRNA expression pattern in healthy individuals and colon polyp and colon cancer patients. (A) The endoscopic diagnosis of healthy individuals (left panel) and colon polyp (central panel) and colon cancer (right panel) patients. (B) The schematic diagram of Arraystar assay performance in plasma circRNAs. (C) The differential expression of plasma circRNAs in polyp patients ( N = 5) and healthy individuals ( N = 5). The expression variation of circRNAs was assessed by the scatter plot between polyp patients and healthy individuals (left panel). The green lines represented fold change lines. The circRNAs above the top green line and below the bottom green line indicated more than 1.5-fold change of circRNAs between the two compared samples. The differential expression of circRNAs was analyzed by volcano plots between polyp patients and healthy individuals (right panel). Red points represented the differentially expressed circRNAs with statistical significance (1.5-fold upregulation and downregulation, P < 0.05). (D) The differential expression of plasma circRNAs in colon cancer ( N = 5) and colon polyp patients ( N = 5). The expression variation of circRNAs was assessed by the scatter plot between colon cancer and colon polyp patients (left panel). The green lines represented fold change lines. The circRNAs above the top green line and below the bottom green line indicated more than 1.5-fold change of circRNAs between the two compared samples. The differential expression of circRNAs was analyzed by volcano plots between colon cancer and colon polyp patients (right panel). Red points represented the differentially expressed circRNAs with statistical significance (1.5-fold upregulation and downregulation, P < 0.05). (E) The differential expression of plasma circRNAs in colon cancer patients ( N = 5) and healthy individuals ( N = 5). The expression variation of circRNAs was assessed by the scatter plot between colon cancer patients and healthy individuals (left panel). The green lines represented fold change lines. The circRNAs above the top green line and below the bottom green line indicated more than 1.5-fold change of circRNAs between the two compared samples. The differential expression of circRNAs was analyzed by volcano plots between cancer patients and healthy individuals (right panel). Red points represented the differentially expressed circRNAs with statistical significance (1.5-fold upregulation and downregulation, P < 0.05). (F–H) The composition of types in detectable circRNAs. (F) The composition of circRNA types in polyp and colon cancer patients. (I) The Venn analysis between upregulated circRNAs from colon cancer patients compared with colon polyp patients and downregulated circRNAs from colon polyp patients compared with healthy individuals. (J) The Venn analysis between downregulated circRNAs from colon cancer patients compared with colon polyp patients and upregulated circRNAs from colon polyp patients compared with healthy individuals. (K) The potential circRNA candidates were validated by performing real-time PCR in plasma from healthy individuals ( N = 15) and colon polyp ( N = 15) and colon cancer ( N = 15) patients. (L) The schematic diagram of circHADHA dynamic alteration in healthy individuals and colon polyp and colon cancer patients. **** P < 0.0001; ns, no significant difference.

Journal: Frontiers in Oncology

Article Title: CircHADHA-augmented autophagy suppresses tumor growth of colon cancer by regulating autophagy-related gene via miR-361

doi: 10.3389/fonc.2022.937209

Figure Lengend Snippet: Plasma circRNA expression pattern in healthy individuals and colon polyp and colon cancer patients. (A) The endoscopic diagnosis of healthy individuals (left panel) and colon polyp (central panel) and colon cancer (right panel) patients. (B) The schematic diagram of Arraystar assay performance in plasma circRNAs. (C) The differential expression of plasma circRNAs in polyp patients ( N = 5) and healthy individuals ( N = 5). The expression variation of circRNAs was assessed by the scatter plot between polyp patients and healthy individuals (left panel). The green lines represented fold change lines. The circRNAs above the top green line and below the bottom green line indicated more than 1.5-fold change of circRNAs between the two compared samples. The differential expression of circRNAs was analyzed by volcano plots between polyp patients and healthy individuals (right panel). Red points represented the differentially expressed circRNAs with statistical significance (1.5-fold upregulation and downregulation, P < 0.05). (D) The differential expression of plasma circRNAs in colon cancer ( N = 5) and colon polyp patients ( N = 5). The expression variation of circRNAs was assessed by the scatter plot between colon cancer and colon polyp patients (left panel). The green lines represented fold change lines. The circRNAs above the top green line and below the bottom green line indicated more than 1.5-fold change of circRNAs between the two compared samples. The differential expression of circRNAs was analyzed by volcano plots between colon cancer and colon polyp patients (right panel). Red points represented the differentially expressed circRNAs with statistical significance (1.5-fold upregulation and downregulation, P < 0.05). (E) The differential expression of plasma circRNAs in colon cancer patients ( N = 5) and healthy individuals ( N = 5). The expression variation of circRNAs was assessed by the scatter plot between colon cancer patients and healthy individuals (left panel). The green lines represented fold change lines. The circRNAs above the top green line and below the bottom green line indicated more than 1.5-fold change of circRNAs between the two compared samples. The differential expression of circRNAs was analyzed by volcano plots between cancer patients and healthy individuals (right panel). Red points represented the differentially expressed circRNAs with statistical significance (1.5-fold upregulation and downregulation, P < 0.05). (F–H) The composition of types in detectable circRNAs. (F) The composition of circRNA types in polyp and colon cancer patients. (I) The Venn analysis between upregulated circRNAs from colon cancer patients compared with colon polyp patients and downregulated circRNAs from colon polyp patients compared with healthy individuals. (J) The Venn analysis between downregulated circRNAs from colon cancer patients compared with colon polyp patients and upregulated circRNAs from colon polyp patients compared with healthy individuals. (K) The potential circRNA candidates were validated by performing real-time PCR in plasma from healthy individuals ( N = 15) and colon polyp ( N = 15) and colon cancer ( N = 15) patients. (L) The schematic diagram of circHADHA dynamic alteration in healthy individuals and colon polyp and colon cancer patients. **** P < 0.0001; ns, no significant difference.

Article Snippet: We collected plasma from healthy individuals and colon polyp and colon cancer patients confirmed by endoscopic diagnosis ( ) and analyzed 2,162 human circRNAs by Arraystar ( ).

Techniques: Clinical Proteomics, Expressing, Biomarker Discovery, Quantitative Proteomics, Real-time Polymerase Chain Reaction

A novel up-regulated circRNA circ-ANXA7 is an independent prognostic factor for LUAD. a circ-ANXA7 up-regulation was found between LUAD tissues (n = 40) and non-tumor tissues (n = 40) by microarray analysis. Red: up-regulation and green: down-regulation. b Box plots visualizing a higher expression level of circ-ANXA7 in LUAD tissues than non-tumor tissues using qRT-PCR. c qRT-PCR was utilized to examine the relative expression levels of circ-ANXA7 between normal epithelial cells and LUAD cells. d Overall survival analysis between LUAD patients with high circ-ANXA7 expression and those with its low expression. e Multivariate regression analysis of circ-ANXA7 expression after adjusting other prognostic factors. f Western blot was presented to examine the expression of ANXA7 protein between normal epithelial cells and LUAD cells. g Immunohistochemistry of ANXA7 between adjacent normal tissues and LUAD tissues. Magnification: ×40; ×200. **p < 0.01

Journal: Cancer Cell International

Article Title: circ-ANXA7 facilitates lung adenocarcinoma progression via miR-331/LAD1 axis

doi: 10.1186/s12935-021-01791-5

Figure Lengend Snippet: A novel up-regulated circRNA circ-ANXA7 is an independent prognostic factor for LUAD. a circ-ANXA7 up-regulation was found between LUAD tissues (n = 40) and non-tumor tissues (n = 40) by microarray analysis. Red: up-regulation and green: down-regulation. b Box plots visualizing a higher expression level of circ-ANXA7 in LUAD tissues than non-tumor tissues using qRT-PCR. c qRT-PCR was utilized to examine the relative expression levels of circ-ANXA7 between normal epithelial cells and LUAD cells. d Overall survival analysis between LUAD patients with high circ-ANXA7 expression and those with its low expression. e Multivariate regression analysis of circ-ANXA7 expression after adjusting other prognostic factors. f Western blot was presented to examine the expression of ANXA7 protein between normal epithelial cells and LUAD cells. g Immunohistochemistry of ANXA7 between adjacent normal tissues and LUAD tissues. Magnification: ×40; ×200. **p < 0.01

Article Snippet: Arraystar Human circRNA Microarray analysis (Arraystar Inc., Rockville, MD, USA) was then presented.

Techniques: Microarray, Expressing, Quantitative RT-PCR, Western Blot, Immunohistochemistry

circ-ANXA7 could directly target the expression of miR-331. a A schematic diagram showing the putative binding sites between circ-ANXA7 and miR-331. b MiRNA microarray expression profiles identified down-regulated miR-331 between LUAD tumor tissues and non-tumor tissues, which was verified by RT-qPCR. c Down-regulated miR-331 was determined in LUAD cells compared to controls by RT-qPCR. d RT-qPCR was utilized to examine miR-331 expression in A549 cells under transfection of pcDNA3.1-circ-ANXA7 and/or miR-331 mimics. e miR-331 expression was determined in A549 cells transfected with sh-circ-ANXA7 and/or miR-331 inhibitor. f Dual luciferase report between circ-ANXA7 and miR-331. g Correlation between circ-ANXA7 and miR-331. **p < 0.01

Journal: Cancer Cell International

Article Title: circ-ANXA7 facilitates lung adenocarcinoma progression via miR-331/LAD1 axis

doi: 10.1186/s12935-021-01791-5

Figure Lengend Snippet: circ-ANXA7 could directly target the expression of miR-331. a A schematic diagram showing the putative binding sites between circ-ANXA7 and miR-331. b MiRNA microarray expression profiles identified down-regulated miR-331 between LUAD tumor tissues and non-tumor tissues, which was verified by RT-qPCR. c Down-regulated miR-331 was determined in LUAD cells compared to controls by RT-qPCR. d RT-qPCR was utilized to examine miR-331 expression in A549 cells under transfection of pcDNA3.1-circ-ANXA7 and/or miR-331 mimics. e miR-331 expression was determined in A549 cells transfected with sh-circ-ANXA7 and/or miR-331 inhibitor. f Dual luciferase report between circ-ANXA7 and miR-331. g Correlation between circ-ANXA7 and miR-331. **p < 0.01

Article Snippet: Arraystar Human circRNA Microarray analysis (Arraystar Inc., Rockville, MD, USA) was then presented.

Techniques: Expressing, Binding Assay, Microarray, Quantitative RT-PCR, Transfection, Luciferase